CVB
CURVEBEAM AI LIMITED
$0.0230
▲ +15.00%
Market cap
$20M
Turnover
$2,784,977
Last price
$0.0230
Day change
+15.00%
Announcements
13
Range, past year
Open 0.086 · Low 0.016 · Now 0.023 · High 0.175
Open CVB in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
CVB momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-10-13.
Momentum quality
38/100
Wyckoff phase
Downtrend9d
Trend stage
Breakdown
1 Day
+15.0%
1 Week
+4.5%
1 Month
+15.0%
1 Year
-73.9%
RSI
52
Avg daily range
11.6%
CURVEBEAM AI LIMITED scores 38 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Downtrend, where it has been for 9 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently outperforming and the institutional accumulation signal reads low.
What stands out
- Volume 2.7× 60-day avg
Points to watch
- 60d drawdown -37.5%
- High volatility (ATR 11.6%)
- Risk rating: Very High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsCVB announcements
Recent price-sensitive releases.
- 2026-10-13 CVB Achieves NMPA Approval for HiRise in China Trading Halt Lifted | Progress Report
- 2026-10-12 Trading Halt Trading Halt
- 2026-09-18 Oversubscribed Shortfall Offer & Placement raise 1.75m Placement | Security Purchase Plan
- 2026-09-15 FDA 510(k) Clearance CT-based BMD Technology Progress Report
- 2026-09-01 SPP Offer Results Security Purchase Plan
- 2026-08-31 Annual Report to shareholders - FY2026 Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-07-08 Quarterly Activities/Appendix 4C Cash Flow Report
More Health Care stocks
Most traded in the same sector.